


DRUGS IN HYPERTENSION

Principles of drug therapy


Prof Asita de Silva

Stroke, Coronary Heart Disease, and Blood Pressure

Risk Ratio



Risk Ratio




MacMahon S. *J Hypertens.* 1990;8(suppl):239-244.

High systolic BP is associated with similar risk

SBP in acute ischaemic stroke: IST

Hypertension is very common in acute ischaemic stroke affecting ~80% of patients



High blood pressure

- Hypertension – one of the most important preventable causes of mortality/morbidity
- Primary / essential hypertension – no cure
- ? Secondary – especially in your hypertensives
- Sri Lanka – 18.8% prevalence
- Generally poorly managed with high CVD morbidity
 - poor compliance
 - monotherapy

Treatment of hypertension

- Non-pharmacological (lifestyle changes)
- Pharmacological

Recent meta analyses have shown ...

- Benefits of BP lowering – due to degree of BP control as well as the class of drug used
- Selection of drug – tailored to suit each patient
- Long acting CCBs – **first line therapy**

Are safe in patients with DM & hypertension

Free of metabolic adverse reactions


No need for investigations related to drug effects

- In the US, only 30-50% hypertensives have adequate BP control
- Many effective drugs are available
- Knowledge of their MoA & sites of action – allows accurate prediction of efficacy & safety
- Rational use of these drugs alone or in combination at the correct doses – lowers BP with minimal risk of serious toxicity

Goals of treatment

- **60 years or older:** <150 / 90 mmHg
- **30-59 years:** DBP <90 mmHg; ? Systolic goal
- **Younger than 30:** ? diastolic goal
- **For these groups:** <140 90 mmHg
- **Hypertensives with DM, non-diabetic CKD:** same goals and thresholds as above

Regulation of BP




Drug therapy – classes of drugs

- Calcium channel blockers (long-acting)*
- Thiazide diuretics*
- ACE inhibitors*
- AT-II receptor blockers*
- Beta-blockers
- Alpha receptor blockers

* Recommended as first-line by JNC 8; 2014

Ca²⁺ channel blockers - CCB



Ca²⁺ channel blockers

- Mainly affect heart & vascular smooth muscle
- Therefore, in addition to antianginal & antiarrhythmic effects CCBs also reduce peripheral resistance & BP
- Block voltage-depend. L-type Ca²⁺ channels
- Most smooth muscle cells – depend on Ca²⁺ influx for resting tone & contractile response – these cells are relaxed by CCBs
- Given orally as well as parenterally
- Three groups - **Verapamil, Diltiazem, Dihydropyridines**
- Selectivity between heart & smooth muscle varies

Dihydropyridines

- Acts mainly on vascular smooth muscle - vasodilatation
- Vasodilator effect - mainly arterioles, not veins
- Those with longer half-lives (**amlodipine, felodipine**) or sustained release preparations (**long acting nifedipine**) – first line therapy
- Short acting preparations – not recommended
- Reflex tachycardia maintains / increased CO
- Common A/E: flushing, headache, ankle swelling
- **Nimodipine** – particularly selective for cerebral vessels

Ca²⁺ channel blockers

Clinical uses

- Hypertension
- Angina (variant angina)
- Supraventricular tachyarrhythmias
- Migraine prophylaxis

Thiazide Diuretics

- Widely used in uncomplicated hypertension
 - HCT, bendrofluazide, (metolazone)
- Mechanism of action – unknown
 - Initially diuresis - reduced blood volume & CO
 - Reduced vascular resist 2^{ry} to removal of NaCl
 - Opening of K_{ATP} channels - resistant arteries
- Usually given once a day (activity for 12-24 h)

Thiazide diuretics


Adverse effects - ↓K / Na, DM, Gout, impotence,
↑ LDL, ↓HDL, ↑renin

Thiazides - given orally at lowest possible dose
(e.g. HCT 12.5 mg o.d. in the morning)

Higher doses don't ↓ BP, but ↑ adverse effects


If a diuretic not chosen as 1st line - usually indicated
as add-on therapy

In severe hypertension – thiazides combined with
vasodilators to reduce Na retention



- Antihypertensive action
- Kaliuretic action

Angiotensin II Plays a Central Role in Organ Damage




*preclinical data

LV = left ventricular; MI = myocardial infarction; GFR = glomerular filtration rate

Adapted from Willenheimer R et al *Eur Heart J* 1999; 20(14): 997-1008, Dahlöf B *J Hum Hypertens* 1995; 9(suppl 5): S37-S44, Daugherty A et al *J Clin Invest* 2000; 105(11): 1605-1612, Fyhrquist F et al *J Hum Hypertens* 1995; 9(suppl 5): S19-S24, Booz GW, Baker KM *Heart Fail Rev* 1998; 3: 125-130, Beers MH, Berkow R, eds. *The Merck Manual of Diagnosis and Therapy*. 17th ed. Whitehouse Station, NJ: Merck Research Laboratories 1999: 1682-1704, Anderson S *Exp Nephrol* 1996; 4(suppl 1): 34-40, Fogo AB *Am J Kidney Dis* 2000; 35(2):179-188

Drugs acting on R-A system



ACE inhibitors

- Dilate capacitance & resistance vessels
 - reduce cardiac load & BP
- Clinically used in
 - Hypertension
 - Cardiac failure (AT II causes LVH)
 - MI (especially when HF is present)
 - Diabetic nephropathy (types I & II)

ACE inhibitors & BP

- Small fall in BP of normal people
- Large fall in hypertensives (with increased renin)
- First-line – patients aged ≥ 18 years with CKD
- Act mainly on angiotensin-sensitive vascular beds
 - kidney, heart & brain
- Selectivity useful - perfusion to vital organs
- Renal artery stenosis is an exception to this

Adverse effects

- Dry cough (? due to bradykinin)
- Hyperkalaemia, proteinuria – investigations done at initiation of drug therapy
- Hypotension - especially with first dose

Contraindications

- Renovascular disease (renal artery stenosis)
- Pregnancy
- Hypersensitivity
- Aortic stenosis

Effects of A II at AT₁ and AT₂ Receptors



AT₁

*Sensitive to blockade
by ARBs*

Vasoconstriction
Aldosterone release
Oxidative stress
Vasopressin release
SNS activation
Inhibits renin release
Renal Na⁺ & H₂O reabsorption
Cell growth & proliferation

AT₂

Vasodilation
Antiproliferation
Apoptosis
Antidiuresis/antinatriuresis
Bradykinin production
NO release

Angio II (AT 1) receptor blockers

Losartan / Valsartan / Candesartan

- Theoretically more effective than ACEIs – more complete inhibition of AT II
- Similar efficacy to ACE inhibitors in patients with HF and chronic kidney disease
- Less adverse effects - useful in those who develop cough with ACEIs
- Usually given orally once daily

Beta-receptor antagonists

- Not widely recommended as first-line treatment
- Reduces BP gradually in hypertensives
- Mechanism of action - complex
 - reduction in cardiac output:
 - reduction in renin release
 - reduced central sympathetic activity
 - block pre-synaptic beta receptors – reduce release of NA

Beta blockers

Propranolol, atenolol, metoprolol, carvedilol

- More cardio-selective drugs preferred
- Atenolol (β_1 selective) preferred to propranolol
 - less effect on airway beta receptors
 - convenient once daily dosing
 - water soluble; less CNS related adverse effects
- Trend to use lower doses - less adverse effects
- Recent studies – metoprolol more effective in preventing complications of hypertension

Beta-blockers (adverse effects)

- Bronchoconstriction - mainly in asthmatics
- Fatigue
- Cardiac failure
- Bradycardia - life threatening heart block
- Hypoglycaemia - avoid in uncontrolled DM
- Cold extremities (less with beta-1 selective)
- Withdrawal syndrome – not discontinued abruptly

Beta-blockers: clinical uses

- Hypertension, Angina
- Following MI / heart failure – Carvedilol
- Cardiac arrhythmias
- Thyrotoxicosis (e.g. before surgery)
- Migraine prophylaxis
- Anxiety, Benign essential tremor
- Glaucoma - Timolol as eye drops

alpha₁-receptor antagonists (Prazosin)

- Vasodilatation - block NA at postsynaptic α_1 -receptors
- May be used with other anti-hypertensives
- Potentially useful in hypertensives with CHF & prostate hyperplasia
- ↓ LDL, VLDL, total TGs & ↑ HDL - beneficial effects in coronary artery disease
- Doxazosin / terazosin - require only o.d. dosing
- Main adverse effects - postural hypotension, dizziness, fatigue, ejaculation failure, priapism

Other anti-hypertensive drugs

- Methyldopa - pregnancy related hypertension
- K channel activators - diazoxide, minoxidil, pinacidil, cromakalim
- Nitroprusside - for hypertensive emergencies & for controlled hypotension in surgery
 - Very short half life: given as an i.v. infusion
- Hydralazine - acts mainly on arteries/arterioles SLE-like syndrome limits its use

Hypertensive emergencies

- BP has to be lowered urgently
- Hospitalized if:
 - Hypertensive encephalopathy
 - Acute LVF (due to hypertension)
 - Aortic dissection
 - Pregnancy induced - eclampsia
- Nitroprusside, hydralazine (pregnancy), GTN infusion, CCB i.v. (nicardipine , clevidipine)

Guidelines for therapy

- Lifelong therapy
- Quality of life
- Economic considerations
- Frequent assessment for end-organ damage
- Concomitant diseases
- Drug interactions - e.g. NSAIDs
- Use recommended / appropriate drugs alone or in combination